Text Size

Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy

This study is currently recruiting participants.
Verified September 2012 by iOMEDICO AG
Sponsor:
Information provided by (Responsible Party):
iOMEDICO AG
ClinicalTrials.gov Identifier:
NCT01192919
First received: August 30, 2010
Last updated: September 17, 2012
Last verified: September 2012
History of Changes
  Purpose

Overview of actually used therapy forms in patients with bronchial carcinoma requiring treatment.


Condition
Observational Study
Registry

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy.

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lung Cancer
U.S. FDA Resources

Further study details as provided by iOMEDICO AG:

Primary Outcome Measures:
  • Documentation of actually used therapy forms in bronchial carcinoma requiring treatment [ Time Frame: 3 years per patient ] [ Designated as safety issue: No ]

Estimated Enrollment: 2500
Study Start Date: January 2010
Estimated Study Completion Date: September 2016
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients with lung cancer
Patients with lung cancer requiring therapy

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients with lung cancer requiring therapy

Criteria

Inclusion Criteria:

  • all patients suffering from Small Cell Lung Cancer (SCLC), Non Small Lung Cancer (NSCLC) or neuroendocrine tumors receiving therapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01192919

Contacts
Contact: Stefanie Kopfmann +4976115242 ext 0 info@iomedico.com

Locations
Germany
Germany Multiple Sites All Over Germany Recruiting Multiple Sites, Germany Contact: iOMEDICO AG Recruiting
Freiburg, Germany, 79108
Contact: Stefanie Kopfmann     +4976115242 ext 0     info@iomedico.com    
Sponsors and Collaborators
iOMEDICO AG
Investigators
Principal Investigator: Hans-Werner Tessen, MD
  More Information

No publications provided

Responsible Party: iOMEDICO AG
ClinicalTrials.gov Identifier: NCT01192919     History of Changes
Other Study ID Numbers: IOM TLK
Study First Received: August 30, 2010
Last Updated: September 17, 2012
Health Authority: Germany: Ethics Commission

Keywords provided by iOMEDICO AG:
bronchial carcinoma
progression free survival
registry
therapy-reality
observation
therapy sequences
 NSCLC
SCLC
Germany
Erlotinib
Bevacizumab
Pemetrexed

Additional relevant MeSH terms:
Lung Neoplasms
Neuroendocrine Tumors
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
 Lung Diseases
Respiratory Tract Diseases
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on May 23, 2013